A new generation of recombinant polypeptides combines multiple protein domains for effective antimicrobial activity

Ramon Roca-Pinilla, Adrià López-Cano, Cristina Saubi, Elena García-Fruitós* and Anna Arís*

Abstract

Background: Although most of antimicrobial peptides (AMPs), being relatively short, are produced by chemical synthesis, several AMPs have been produced using recombinant technology. However, AMPs could be cytotoxic to the producer cell, and if small they can be easily degraded. The objective of this study was to produce a multidomain antimicrobial protein based on recombinant protein nanoclusters to increase the yield, stability and effectiveness.

Results: A single antimicrobial polypeptide JAMF1 that combines three functional domains based on human α-defensin-5, human XII-A secreted phospholipase A2 (sPLA₂), and a gelsolin-based bacterial-binding domain along with two aggregation-seeding domains based on leucine zippers was successfully produced with no toxic effects for the producer cell and mainly in a nanocluster structure. Both, the nanocluster and solubilized format of the protein showed a clear antimicrobial effect against a broad spectrum of Gram-negative and Gram-positive bacteria, including multi-resistant strains, with an optimal concentration between 1 and 10 µM.

Conclusions: Our findings demonstrated that multidomain antimicrobial proteins forming nanoclusters can be efficiently produced in recombinant bacteria, being a novel and valuable strategy to create a versatile, highly stable and easily editable multidomain constructs with a broad-spectrum antimicrobial activity in both soluble and nanostructured format.

Keywords: Antimicrobial peptides, Antimicrobial resistance, Inclusion bodies, Multidomain protein, Solubilization, Recombinant production, Protein nanoclusters

Background

The growing number of antibiotic-resistant pathogens is a pressing healthcare challenge. As a consequence, the development of novel antimicrobial drugs is more necessary than ever, especially against multidrug-resistant (MDR) microorganisms. One source of potential broad-spectrum antibacterials with increasing promise are antimicrobial peptides (AMPs), which are peptides from the innate immune system of nearly all multicellular organisms [1, 2]. AMPs also known as host defense peptides (HDPs), are cationic amphiphilic peptides [3]. These positively charged peptides are classified into defensins (alpha-defensins and beta-defensins), cathelicidins, and histatins [1]. Because they interact and disrupt the negatively charged bacterial cell envelope, they have broad-spectrum antibacterial activity [4, 5]. Although AMPs hold therapeutic potential, even against MDR bacteria [4–6], important drawbacks largely hinder final in vivo applications [3]. Most of the currently used AMP are produced by chemical synthesis, being molecules highly susceptibility to proteolytic degradation by microbial and host enzymes (short half-life) [7]. Besides, due to the high doses needed they are frequently toxic and high production costs are still a problem for large-scale development [8]. Alternatively, AMPs can...
be recombinantly produced [9–11]. Still, their small size makes them easily degradable, and their recombinant production is limited because they are toxic for the producer bacterial cell due to their antimicrobial nature. To address these shortcomings, different approaches to make the production of recombinant AMPs linked to a carrier that stabilizes the peptide have been described. Some examples of carriers for these fusion proteins are small ubiquitin-like modifier (SUMO), thioredoxin (Trx), glutathione S-transferase (GST), biotin carboxyl carrier protein (BCCP), green fluorescent protein (GFP), calmodulin and human serum albumin [12–15]. Another strategy to efficiently produce these peptides is the use of acidic partners [16]. In all the cases, these carriers or partners help to overcome the toxicity of the AMP and at the same time increase their protein expression yields [16–18]. However, to retrieve the AMP of interest, it is often necessary to remove these carriers, which requires expensive enzymatic cleavage or toxic reagents [19].

To address this gap, here, we have explored a new strategy for the production of a recombinant antimicrobial protein based on a multidomain polypeptide that combines different functional domains in a single molecule but without a carrier protein. The combination of several domains has been previously reported for other proteins [20–23], but none of them for antimicrobial treatment purposes. Additionally, taking into consideration the specific requirements of price, stability, toxicity, effectiveness, and delivery that appear to be key parameters in the development of a new generation of antimicrobials [3], we have added aggregation-seeding domains based on leucine zippers that increase the recombinant production of the antimicrobial molecules as protein nanoclusters (also known as inclusion bodies (IBs)) [24]. IBs are non-enveloped, porous and mechanically stable protein nanoparticles, mainly formed by the polypeptide of interest and generated during recombinant protein production process, having the potential to be a protein-slow release form when administered [25]. Another advantage of this protein format is its production through a one step-process. This means that, in contrast to most of encapsulation strategies, which involve two separate processes (the production of the carriers and the biomolecule separately), IB production is achieved in one single step. Finally, it has also been previously proven that IBs can be used as a source of soluble protein after a mild extraction protocol in non-denaturing conditions [26, 27].

**Results and discussion**

**Construct design and protein production of JAMF1 as protein nanocluster**

Our construct, named JAMF1 and formed by the combination of an HDP (HD5) [28], a bacterial binding domain (gelsolin) [29] and an enzymatic antimicrobial peptide (sPLA₂) [30], flanked by two aggregation-seeding domains (c-Jun and c-Fos leucine zippers at N- and C-terminal, respectively), has been designed (Fig. 1 and Additional file 1: Figure S1). During their production in a recombinant bacterial system, no toxicity effects were observed in the producer cell (data not shown) and, as desired, the multidomain JAMF1 protein (54 kDa) was mainly produced as protein IBs (Additional file 1: Figure S2). The percentage of JAMF1 aggregation as IBs was 74±3.1% of the total multidomain protein overproduced, reaching a yield of 96.5 mg/l and a purity of 95% once purified. FESEM micrographs of the purified JAMF1 IBs showed a porous morphology with a round shape and a particle size of around 500 nm (Fig. 1).

**Antibacterial activity of JAMF1 nanoclusters**

To determine the antimicrobial activity of JAMF1 IBs, we evaluated the survival of both Gram-positive and Gram-negative pathogenic bacteria treated with JAMF1 IBs, following the procedure described in Fig. 2a. First, the survival of an E. coli DH5α model strain in presence of increasing concentrations of JAMF1 IBs was determined and a dose dependent effect was observed (p \( \leq 0.01 \)) (Fig. 2b). Using the concentration of JAMF1 IBs giving the lowest values of E. coli survival (10 μM), we tested the antibacterial effect of these nanoparticles with different Gram-positive strains, including extended-spectrum beta-lactam-resistant Enterococcus spp. (SHV-12), extended-spectrum beta-lactam-resistant Enterococcus spp. (CTX-M-14), and E. faecalis (ECF), and Gram-negative strains, including Carabapenem-resistant Klebsiella pneumoniae (KPC), quinolone-resistant K. pneumoniae (qnrA), and extended-spectrum beta-lactam-resistant E. coli (CMY2) (Fig. 2c). In all strains tested we observed a clear decrease in the survival (p \( \leq 0.001 \)), reaching viability reduction values of 96.3 ± 0.2% for KPC, 91 ± 0.2% for qnrA, 85.3 ± 0.6 for CMY2, 82.8 ± 2% for SHV-12, 89.8 ± 0.9% for ECF, and 94.4 ± 0.7% for CTX-M-14 (Fig. 2c).

**Anti-biofilm activity of JAMF1 nanoclusters**

To further evaluate the potential of this new class of antimicrobial proteins we have assessed the capacity of JAMF1 nanoclusters to inhibit biofilm formation. For that, KPC was grown in multiwell plates in which JAMF1 IBs (sPLA₂) were previously immobilized, as detailed in Fig. 3a. The results obtained showed a decrease of 81.4 ± 2.3% in biofilm formation (p \( \leq 0.0001 \)) when surfaces were decorated with JAMF1 IBs (Fig. 3b), which confirms that antimicrobial nanoclusters are also active when deposited on plastic surfaces to inhibit biofilm formation.

Several works have studied the IBs appealing features in contexts such as cancer [31], tissue regeneration [32],
**Fig. 1** Construct design. Schematic representation of JAMF1 protein construct and protein production format. Inset image: FESEM micrography of purified JAMF1 nanoparticles.

**Fig. 2** Antibacterial activity of JAMF1 nanoclusters. 

**a** Graphic representation of the BacTiter-Glo™ Microbial Cell viability assay. 

**b** Bacterial survival (%) of E. coli DH5α in the presence of JAMF1 IBs at a range of 0-10 µM. Different letters describe significant differences (p ≤ 0.01). 

**c** Bacterial survival of KPC, qnrA, CMY2, SHV-12, ECF and CTX-M-14 bacterial strains in the presence of 10 µM of JAMF1 IBs. Survival of JAMF1 treated bacterial cells (black bars) is significantly different from the negative control (grey bars) (p ≤ 0.001).
and immunostimulation [33], demonstrating its great potential as a new biomaterial. However, to the best of our knowledge, this is the first study exploring the antimicrobial effect of a multidomain protein embedded in IBs. Whereas previous studies have used fusion partners such as SUMO [12], Trx, GST [13], and human serum albumin [14] to overcome the difficulties to express relatively short peptides, the current work shows that it is also possible to produce a non-toxic and stable AMP-based molecule as a combination of several AMPs. This offers versatility in the construction of molecules and the possibility to explore several combinations to merge complementary antimicrobial activities without the need to use biologically irrelevant carrier proteins. The production of this new generation of antimicrobial multidomain polypeptides as nanoclusters seems to be a good strategy to escape proteolytic and host-toxicity pathways in the recombinant bacterial host.

Solubilized JAMF1 antibacterial activities
For some specific applications a soluble version of the multidomain antimicrobial polypeptide would be more appropriate than the nanostructured or IBs version, for example those applications in which an intravenous administration of the protein would be necessary. Interestingly, the IB format has also been previously described as a reservoir of functional protein [25] and, in consequence, an appealing source of the soluble version of proteins tricky to produce, available after using a mild-extraction protocol [26]. Considering that JAMF1 is mainly produced as IBs (74% of the total protein overproduced), we also explored if JAMF1 IBs could be used as a source to obtain pure antimicrobial multidomain polypeptide in its soluble form using a non-denaturing protocol and evaluate its antimicrobial potential (Fig. 4a). The results proved that the purified soluble version could not only be isolated from IBs (Additional file 1: Figure S2) but also showed antimicrobial activity against either E. coli (p ≤ 0.0001) and KPC (p ≤ 0.001) in a dose-dependent manner, where the growth inhibition reached values of 78.7 ± 2% and 91.3 ± 8.5% for E. coli and KPC at 3 and 2 μM, respectively (p < 0.0001) (Fig. 4b). Interestingly, the antimicrobial efficiency of this new multidomain antimicrobial molecule is pretty similar at 3 μM, achieving efficiencies of around 78% in both cases (Figs. 2b and 4b). This contrasts with the majority of examples comparing the activity of soluble and IB formats, in which the soluble version is usually more biologically active that its nanoclustered counterpart [34].

Conclusions
Our findings demonstrated that multidomain antimicrobial proteins produced as nanoclusters can be efficiently obtained in recombinant bacteria, being a valuable strategy to create a versatile, highly stable and easily editable constructs with antimicrobial activity against both Gram-positive and Gram-negative bacteria. Moreover, we have proven that the antimicrobial protein forming the IBs can be easily solubilized to obtain also active proteins in its soluble form.

Methods
Bacterial strains and medium
Escherichia coli BL21 (DE3) was used for heterologous protein expression. Strains used for antibacterial and antibiofilm activity assays were E. coli DH5α, Carbapenem-resistant Klebsiella pneumoniae (KPC), quinolone-resistant K. pneumoniae (qnrA), extended-spectrum
beta-lactam-resistant *E. coli* (CMY2), extended-spectrum beta-lactam-resistant *Enterococcus* spp. (SHV-12), extended-spectrum beta-lactam-resistant *Enterococcus* spp. (CTX-M-14) and *E. faecalis* (ECF). All strains were grown in Brain–Heart Infusion (BHI) broth (Scharlau, Barcelona, Spain), except for *E. coli* strains, which were grown in Luria–Bertani (LB) medium.

**Genetic construct design**

From N-terminal to C-terminal, the gene for the JAMF1 (Additional files 2, 3, 4) construct consisted of the sequences encoding Jun257-318 (Uniprot entry P05412), human α-defensin-5 (HD5) precursor (Uniprot entry Q01523), gelsolin188-196 (Uniprot entry P06396), human XII-A secreted phospholipase A2 (sPLA2) precursor (Uniprot entry Q9BZM1) and Fos118-210 (Uniprot entry P01100). A linker sequence (SGGGSGGS) was used between each of the domains and a C-terminal H6-Tag for protein purification. The fusion construct was codon optimized by GeneArt (Life Technologies, Regensburg, Germany) and cloned into pET22b (AmpR) (Novagen, Darmstadt, Germany) vector.

**Inclusion body production and purification**

*Escherichia coli* BL21 (DE3)/pET22b-JAMF1 (Additional file 3) culture (0.5 l) was grown at 37 °C and 250 rpm in LB broth with ampicillin at 100 µg/mL. Protein expression was induced by 1 mM isopropyl-β-d-thiogalactoside (IPTG) at an OD600 = 0.4–0.6. Cultures were grown 3 h post-induction and after that processed as previously described [35]. Briefly, protease inhibitors (Complete EDTA-free, Roche), and phenylmethanesulphonyl fluoride (PMSF) and lysozyme were added to the culture at a final concentration of 0.4 mM (Sigma-Aldrich) and 1 µg/ml (Sigma-Aldrich), respectively. After 2 h of incubation at 37 °C and 250 rpm the culture was centrifuged and resuspended in 50 ml of PBS supplemented with protease inhibitors. Then, the mixture was ice-jacketed and sonicated for 4 cycles of 1.5 min at 10% amplitude under 0.5 s cycles. After sonication, the mixture was frozen overnight (ON) at −80 °C. The mixture was thawed and Triton X-100 was added (0.4% (v/v)) and incubated for 1 h at room temperature (RT). After this treatment, the mixture was frozen at −80 °C for 2 h and then thawed between for several cycles until no viable bacterial growth was detected. After that, 125 µl of Nonidet P40 (NP-40) was added and incubated for 1 h at 4 °C. Then, DNA was removed with DNAse at a final concentration of 0.6 µg/ml and MgSO4 0.6 mM for 1 h at 37 °C and 250 rpm. Samples were centrifuged at 15,000×g for 15 min at 4 °C. The pellet containing IBs was washed with 25 ml lysis buffer (50 mM Tris–HCl pH 8, 100 mM NaCl, 1 mM EDTA and Triton X-100 0.5% (v/v)). The mixture was incubated at 15,000×g and 4 °C for 15 min was carried out obtaining pellets that were stored at −80 °C until analysis. Purified IBs were quantified by western blot using a monoclonal anti-His antibody (His-probe, Santa Cruz).

**IB solubilization and purification of the solubilized JAMF1**

*Escherichia coli* BL21 (DE3)/pET22b-JAMF1 culture (2 l) was grown as previously described. The whole volume was centrifuged at 6000×g and the pellet was resuspended in 120 ml of PBS 1x in presence of protease inhibitors. Samples of 30 ml were subjected to 4 rounds of sonication for 5 min at 10% amplitude under 0.5 s cycle, intercalated by a minimum of 5 min reposes in ice. Protein pellets were recovered and washed twice with distilled water. Pellets were weighted and solubilized in 0.2% N-lauroyl sarcosine, 40 mM Tris and protease inhibitors at a ratio of 40 ml/g of wet pellet as previously described [27]. The mixture was incubated 40 h ON at RT under agitation and the supernatant was recovered through centrifugation at 15,000×g for 45 min at 4 °C.
for further purification. NaCl and imidazole were added to the solubilized protein to equilibrate the samples with the binding buffer composition, and Immobilized Metal Affinity Chromatography (IMAC) purification was carried out in an AKTA purifier FPLC (GE Healthcare, Chicago, IL, USA) using 1 ml HisTrap HP columns (GE Healthcare). Both the binding and the elution buffer contained 0.2% N-lauroyl sarcosine, and the final imidazole concentration in the elution buffer was 0.5 M. The buffer of the selected fractions was changed to 10 mM KPi (K2HPO4 buffer pH 7.4) using a desalting column (GE Healthcare). The amount of purified protein was determined by Bradford’s assay, and the integrity of the protein analyzed by SDS-PAGE [26].

**Antibacterial activity assay**
The bacterial cell viability was assessed with the BacTiter-Glo™ Microbial Cell Viability assay (Promega, Mannheim, Germany), according to the manufacturer’s protocol. Shortly, bacterial cells were grown O/N at 37 °C and 250 rpm and then diluted 1:100 in KPi buffer. Then, 150 µl from the KPi diluted cells were centrifuged in 1 ml tubes at 6200 × g at 4 °C for 15 min. Subsequently, the supernatant was removed, and the pellets cells were then resuspended with 150 µl of either KPi buffer (negative control) or 150 µl of JAMF1 IBs at 1, 3, 5 and 10 µM. After 5 h incubation at 37 °C in a 96-well plate, 100 µl were taken and mixed with 100 µl of the BacTiter-Glo™ reagent. Finally, luminescence was measured in a microplate luminometer (LUMIstar®, BMG LABTECH, Ortenberg, Germany). The measured arbitrary luminescence values were normalized against the control (KPi treatment).

**Biofilm formation assay**
KPC was used as a model strain. Briefly, an O/N was grown at 37 °C and 250 rpm. Before adding bacteria to a 24-well sterile plate for biofilm formation, IB-treated wells were incubated 2 h at RT with 80 µl/well of 500 µM of JAMF1 IBs. After that, bacteria from the O/N culture were diluted 1:200 in BHI supplemented with 0.2% glucose and grown in 24-well sterile plate (400 µl final volume) and incubated at 37 °C for 24 h. After the incubation, the supernatant was removed and wells were washed three times with 500 µl NaCl 0.9%, then fixed with 500 µl methanol for 10 min at RT. Methanol was removed and the plate was dried at 37 °C for 15 min. Finally, the remaining cells in the well were stained with 1% (v/v) crystal violet for 15 min at RT, washed three times with sterile MQ-H2O. Finally, stained cells were diluted in 33% (v/v) acetic acid and the absorbance was measured at 595 nm [36]. All measurements were done by triplicate and in sterile conditions.

**Electron microscopy**
Microdrops of JAMF1 IB suspensions were air-dried on silicon wafers and micrographed in a FESEM Zeiss Merlin (Zeiss) running at 1 kV

**Statistical analysis**
For all assays, each condition was performed in triplicate and represented as the mean ± standard error of the mean. All data were checked for normality. All p-values correspond to ANOVA analyses, except for the biofilm formation assay where a t-test was performed. Letters correspond to Tukey test analyses.

**Supplementary information**
Supplementary information accompanies this paper at https://doi.org/10.1186/s12934-020-01380-7.

**Additional file 1:** Figure S1. Aminoacidic sequence of JAMF1 for each of the construct domains. Figure S2. Western Blots of JAMF1. (a) Expression time course of JAMF1 at 0, 1, 3 and 5 h post-induction with IPTG in the insoluble and soluble fractions. MWM = Molecular Weight Marker (kDa), IF = Insoluble fraction, SF = Soluble fraction. (b) Western blot of the purified JAMF1 by IMAC (PP) and the purified IBs (PBi).

**Additional file 2.** DNA coding sequence of JAMF1.

**Additional file 3.** DNA coding sequence of PET22b-JAMF1.

**Additional file 4.** JAMF1 amionic acid sequence.

**Abbreviations**
AMP: Antimicrobial peptide; sPLA2: Human XII-A secreted phospholipase A2; MDR: Multidrug resistant; IB: Inclusion body; KPC: Carbapenem-resistant Klebsiella pneumoniae; qnrA: Quinolone-resistant K. pneumoniae; CMY2: Extended-spectrum beta-lactam-resistant Escherichia coli; SHV-12: Extended-spectrum beta-lactam-resistant Enterococcus spp; CTX-M-1: Extended-spectrum beta-lactam-resistant Enterococcus spp; ECF: Enterococcus faecalis; BHI: Brain–Heart Infusion; LB: Luria–Bertani broth; HDS: Human α-defensin-5; IPTG: Isopropyl-β-D-thiogalactoside; SUMO: Small ubiquitin-like modifier; Trx: thioredoxin; GST: Glutathione S-transferase; BCCP: Biotin carboxyl carrier protein; GFP: Green fluorescent protein.

**Acknowledgements**
The authors are indebted to ICTS “NANBIOIS”, more specifically the Protein Production Platform of CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER- BBN) in Spain, for providing the electrospinning setup and the necessary equipment. The authors are also grateful to Professor José Manuel Rodríguez-Ridruejo for his advice and the use of the facilities at the Department of Microbiology at the University of Granada. The authors are indebted to ICTS “NANBIOIS”, more specifically the Protein Production Platform of CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER- BBN) in Spain, for providing the electrospinning setup and the necessary equipment. The authors are also grateful to Professor José Manuel Rodríguez-Ridruejo for his advice and the use of the facilities at the Department of Microbiology at the University of Granada.

**Funding**
This work was supported by an IRTA Cutting Edge Research project. We are indebted to CERCA Programme (Generalitat de Catalunya) and the European Social Fund for supporting our research. RRP and ALC received a PhD fellowship from Secretaria d’Universitats i Recerca del Departament d’Economia i Comerç of the Generalitat de Catalunya (AGAUR) and EGF a post-doctoral fellowship from INIA (DOC-INIA).
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 19 April 2020   Accepted: 27 May 2020
Published online: 05 June 2020

References
1. De Smet K, Contreras R. Human antimicrobial peptides: defenses, cathelicidins and histatins. Biotechnol Lett. 2005;27(18):1337–47.
2. Haney EF, Mansour SC, Hancock REW. Antimicrobial peptides: an introduction. In: Methods in molecular biology. 2017. p. 3–22. http://www.ncbi.nlm.nih.gov/pubmed/28013493.
3. Kumar P, Kshakhkedathu J, Straus S. Antimicrobial peptides: diversity, mechanism of action and strategies to improve the activity and biocompatibility in vivo. Biomolecules. 2018;8(1):4.
4. Jiang Z, Mant CT, Vasil M, Hodges RS. Role of positively charged residues on the polar and non-polar faces of amphiarchic α-helical antimicrobial peptides on specificity and selectivity for Gram-negative pathogens. Chem Biol Drug Des. 2018;91:75–92.
5. Greber KE, Dawgul M, Kamysz W, Sawicki W. Catonic net charge and counter ion type as antimicrobial activity determinant factors of short lipopeptides. Front Microbiol. 2017;8:123.
6. Lázár V, Martins A, Soproni R, Daruka L, Grézal G, Felkete G, et al. Antibiotic-resistant bacteria show widespread collateral sensitivity to antimicrobial peptides. Nat Microbiol. 2018;3(6):718–31.
7. da Costa JP, Cova M, Ferreira R, Vitorino R. Antimicrobial peptides: an alternative for innovative medicines? Appl Microbiol Biotechnol. 2015;99(5):2023–40.
8. Vlieghje P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov Today. 2010;15(1–2):40–56.
9. Cao J, de la Fuente-Núñez C, Ou RW, Torres MD, Fande SG, Sinsky AJ, et al. Yeast-based synthetic biology platform for antimicrobial peptide production. ACS Synth Biol. 2018;7(3):896–902. https://doi.org/10.1021/acssynbio.7b00396.
10. Balandin SV, Finkina EI, Nurmukhamedova EKA, Tagaev AA, Umnyakova ES, Kokryakov VN, et al. Biotechnological method of preparation and characterization of recombinant antimicrobial peptide avicin A from Enterococcus avium. Dokl Biochem Biophys. 2019;484(1):42–4.
11. Anju A, Smitha CK, Preetha K, Boobal R, Rosamma P. Molecular characterization, recombinant expression and bioactivity profile of an antimicrobial peptide, Ss-arasin from the Indian mud crab, Scylla serrata. Fish Shellfish Immunol. 2019;88:552–8.
12. Satakanri M, Curtis R. Production of recombinant peptides as fusions with SUMO. Protein Expr Purif. 2011;78(2):113–9. https://doi.org/10.1016/j.pep.2011.04.015.
13. Li Y. Production of human antimicrobial peptide LL-37 in Escherichia coli using a thioredoxin—SUMO dual fusion system. PROTEIN Expr Purif. 2013;87(2):72–8. https://doi.org/10.1016/j.pep.2012.10.008.
14. Wang M, Zheng K, Lin J, Huang M, Ma Y, Li S, et al. Rapid and efficient production of cecropin A antibacterial peptide in Escherichia coli by fusion with a self-aggregating protein. BMC Biotechnol. 2018;18(1).62.
15. Sinha R, Shukla P. Antimicrobial peptides: recent insights on biotechnological interventions and future perspectives. Protein Pept Lett. 2019;26(2):79–87.
16. Wang Y-Q, Cai J-Y. High-level expression of acidic partner-mediated antimicrobial peptide from tandem genes in Escherichia coli. Appl Biochem Biotechnol. 2007;1412–3:203–13.
17. Arias M, Hoffarth ER, Ishida H, Aramini JM, Vogel HJ. Recombinant expression, antimicrobial activity and mechanism of action of tritryptic analogs containing fluoro-tryptophan residues. Biochim Biophys Acta Biomembr. 2016;1858:1012–23.
18. Yi T, Sun S, Huang Y, Chen Y. Prokaryotic expression and mechanism of action of α-helical antimicrobial peptide A20L using fusion tags. BMC Biotechnol. 2015;15(1):1–10. https://doi.org/10.1186/s12896-015-0189-x.
19. Li Y. Self-cleaving fusion tags for recombinant protein production. Biotechnol Lett. 2011;33(5):869–81.
20. Lee H-B, Piao D-C, Lee J-Y, Choi J-Y, Bok J-D, Cho C-S, et al. Artificially designed recombinant protein composed of multiple epitopes of foot-and-mouth disease virus as a vaccine candidate. Microbiol Cell Fact. 2017;16(1):33.
21. Kempe T, Kent SBH, Chow F, Peterson SM, Sundquist WI, Utailen JJ, et al. Multiple-copy genes: production and modification of monomeric peptides from large multimeric fusion proteins. Gene. 1985;392(3):239–45.
22. Skowron PM, Krawczun N, Zebrowska J, Kreft D, Zolnierkiewicz O, Belawa M, et al. A vector-enzymatic DNA fragment amplification-expression methodology for construction of artificial, concatenated DNA, RNA and proteins for novel biomaterials, biomedical and industrial applications. Mater Sci Eng C. 2020;108:110426.
23. Domingo-Espin J, Vázquez E, Ganz J, Conchillo O, García-Fromós E, Cedano J, et al. Nanoparticulate architecture of protein-based artificial viruses is supported by protein–DNA interactions. Nanomedicine. 2011;6(6):1047–61.
24. Choi S, Lee SJ, Yeom S, Kim HJ, Rhee YH, Jung H, et al. Controlled localization of functionally active proteins to inclusion bodies using leucine zippers. PLoS ONE. 2014;9(6):e97093.
25. Rinas U, García-Fromós E, Corchero JL, Vázquez E, Seras-Franzoso J, Villaverde A. Bacterial inclusion bodies: discovering their better half. Trends Biochem Sci. 2017;42(9):726–37.
26. Gihe-Renom L, Cano-Garrido O, Fabregas F, Roca-Pinilla R, Seras-Franzoso J, Ferrer-Filatilles N, et al. A new approach to obtain pure and active proteins from Lactococcus facts protein aggregates. Sci Rep. 2018;8(1):13917.
27. Peterme S, Grđadnik J, Gaberc-Porekar V, Kromel R. Engineering inclusion bodies for non denaturing extraction of functional proteins. Microbiol Cell Fact. 2008;7:1–9.
28. Sefstved ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol. 2005;6:551. https://doi.org/10.1038/nri206.
29. Bucki R, Byfield FJ, Kulakowska A, Mccormick ME, Drozdowski W, Hartung T, et al. Extracellular gelosolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components. J Immunol. 2008;181(7):4936–44.
30. Huhntien HT, Grönoos JO, Grönoos JM, Uksila J, Gellb MH, Nevalainen TJ, et al. Antibacterial effects of human group IIA and group XIIA phospholipase A2 against Helicobacter pylori in vitro. APAMS. 2006;14(2):127–30.
31. Pesarrodona M, Jauset T, Díaz-Riascos ZV, Sánchez-Chardi A, Beaulieu M, Seras-Franzoso J, et al. Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components. J Immunol. 2008;181(7):4936–44.
32. Huhntien HT, Grönoos JO, Grönoos JM, Uksila J, Gellb MH, Nevalainen TJ, et al. Antibacterial effects of human group IIA and group XIIA phospholipase A2 against Helicobacter pylori in vitro. APAMS. 2006;14(2):127–30.
33. Seras-Franzoso J, Peebo K, García-Fromós E, Vázquez E, Rinas U, Villaverde A. Improving protein delivery of fibroblast growth factor-2 from bacterial inclusion bodies used as cell culture substrates. Acta Biomater. 2014;10(3):1354–9.
34. Torrealba D, Parra D, Seras-Franzoso J, Vallejos-Vidal E, Yero D, Gibert I, et al. Nanostructured recombinant cytokines: a highly stable alternative to short-lived prophyllactics. Biomaterials. 2016;107:102–14.
35. García-Fromós E, González-Montañán N, Morell M, Vera A, Ferraz RM, Aris A, et al. Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins. Microbiol Cell Fact. 2005;4:1–6.
36. García-Fromós E editor. Insoluble proteins methods and protocols. New York: Springer; 2015. (Methods in molecular biology; vol. 1258). http://link.springer.com/10.1007/978-1-4939-2205-5.
37. Roca-Pinilla et al. Microb Cell Fact          (2020) 19:122
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.